Unicycive Therapeutics UNCY 深 滬
交易中 10-30 11:56:30 美东时间
4.96
+0.160
+3.33%
華盛通- 最 高5.065
- 今 開4.83
- 成交量 27.20万股
- 最 低 4.765
- 昨 收 4.80
- 總市值 6269.89万
- 52周最高 11.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.71
- 委 比 0.00%
- 總股本 1264.09万
- 歷史最高 87.30
- 量 比 1.14
- 振 幅 6.25%
- 歷史最低 2.02
- 每 手 1
- 風險率 1.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
今天 14:22
Unicycive Therapeutics Plans To Resubmit NDA For Oxylanthanum Carbonate By Year-End
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the Company or Unicycive), today announced an update from its meeting with the
10-28 19:10
Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End
<p>Unicycive Therapeutics announced plans to resubmit its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) by year-end following a constructive FDA meeting. The company aims for a PDUFA date in early 2026. With $42 million in cash, it expects to maintain operations into 2027. OLC, an investigational phosphate binder, offers potential advantages in reducing pill burden for dialysis patients with hyperphosphatemia. The company remains fo...
10-28 11:05
UNCY Lawsuit Alert! Class Action Lawsuit Against Unicycive Therapeutics
Aclass actionlawsuit was filed againstUnicycive Therapeutics ...
09-30 21:18
美股机会日报 | 市场翘首以待！美国8月零售销售数据将公布；甲骨文盘前涨超5%
今晚20:30公布！美国8月零售销售或逆势增长；知名分析师：恐慌性降息周期将开启；甲骨文盘前涨超5%，据报在中美TikTok交易中扮演关键角色>>
09-16 20:13
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $21
Benchmark analyst Bruce D. Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the price target from $3 to $21.
09-15 20:57
Unicycive Therapeutics to Participate in Upcoming Investor Events in September
Unicycive Therapeutics Inc. announced that CEO Shalabh Gupta, M.D., will participate in two investor events in September. The first is a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, and the second is a virtual fireside chat with Truist Securities on September 17, 2025. The company is developing therapies for kidney diseases, including oxylanthanum carbonate for hyperphosphatemia in chronic k...
08-26 11:00
Unicycive Faces Securities Lawsuit Over Drug Claims
Unicycive Therapeutics ( ($UNCY) ) has provided an update. On August 15, 2025, ...
08-19 04:53
